LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $36
Positive Outlook on Larimar Therapeutics' Nomlabofusp for Friedreich's Ataxia: Analyst Recommends Buy Rating
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $21
H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15
Larimar Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
Larimar Therapeutics Analyst Ratings
Citi Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $14
H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $36
Leerink Partners Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
Larimar Therapeutics Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $26
Larimar Therapeutics Analyst Ratings
Wedbush Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $22
H.C. Wainwright Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $15
Larimar Therapeutics Price Target Announced at $15.00/Share by HC Wainwright & Co.
JonesTrading Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $14
Larimar Therapeutics Initiated at Outperform by Baird
No Data